BioBridgeX
Log inCompare quotes
Indication

Allergy / Immunization CRO and CDMO vendors

Free for buyersNeutral vendor of record
Quick answer

Allergy and immunization outsourcing spans allergy programs (allergen immunotherapy, anaphylaxis, asthma overlap) and vaccines. CRO work covers immunogenicity and serology assays, allergen challenge and EEC models, IgE and basophil testing, plus GCP clinical operations; CDMO work covers allergen extracts, adjuvants, and sterile vaccine fill-finish. On BioBridgeX, buyers source and compare vetted vendors free, under one contract, with BioBridgeX as neutral vendor of record.

Allergy / Immunization CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Allergy / Immunization CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does an Allergy / Immunization program need?

Allergy and immunization covers two related but distinct kinds of program, and the outsourcing needs diverge early. Allergy programs (allergic rhinitis, asthma with an allergic component, food allergy, atopic dermatitis, allergen immunotherapy, and acute anaphylaxis) turn on the IgE-driven immune response and on provoking or suppressing it in a controlled way. Immunization programs (prophylactic and therapeutic vaccines, plus adjuvant and platform work) turn on raising a protective response and proving it is durable and safe. A vendor strong in one is not automatically right for the other, so the first job is matching the partner to which side of the field you are on.

On the discovery and preclinical side, the work is heavily immunology. You are buying antigen and allergen characterization, epitope mapping, immunogen design, adjuvant screening, and in vivo immunogenicity in the right sensitized or challenge models: ovalbumin and house-dust-mite sensitization for allergic airway disease, oral sensitization models for food allergy, and the standard immunization-and-challenge designs for vaccines. Good groups here run the functional readouts that actually matter, not just antibody titers: neutralizing antibody and serum bactericidal assays for vaccines, specific IgE and IgG4, basophil activation tests, and T-cell or cytokine profiling for mechanism. Bioanalytical and immunoassay capacity (ELISA, ELISpot, multiplex cytokine panels, flow cytometry) is the workhorse capability you will lean on at almost every stage, and it is worth confirming the lab can validate those assays to support regulatory filings, not just run them for research.

Clinical work in this indication has features you will not see elsewhere. Allergen immunotherapy and food-allergy trials often run on challenge models: environmental exposure chambers (EEC) for aeroallergens, nasal or conjunctival allergen provocation, and double-blind placebo-controlled oral food challenge for food allergy, each of which needs a CRO with the protocols, the dosing-room safety setup, and the trained challenge staff to run them cleanly. Endpoints are symptom and medication scores, challenge thresholds, and patient-reported outcomes rather than survival or tumor response, and they are seasonal: a pollen-allergy field trial is tied to a pollen season, so a missed enrollment window can cost you a year. Vaccine trials bring their own demands: large healthy-volunteer cohorts, pediatric and sometimes elderly populations, cold-chain logistics, reactogenicity diaries, and immunogenicity sampling on a fixed schedule. Across both, expect a real safety apparatus for anaphylaxis and adverse-event reporting, plus the DSMB and pharmacovigilance discipline that comes with dosing healthy or allergic subjects.

How do you choose a CRO for Allergy / Immunization?

The deciding factor is specific experience in your program type and the assays or models it depends on, not general clinical-trial volume. An immunization team and an allergen-challenge team are different specialties, and a vendor that has actually run your kind of study (EEC aeroallergen trials, double-blind oral food challenge, a pediatric vaccine immunogenicity study) brings protocols, safety practice, and trained staff you would otherwise pay them to learn on your program. Where your work is manufacturing rather than testing (allergen extracts, conjugate or subunit vaccines, adjuvant formulation, sterile fill-finish), the same logic points to a CDMO with that exact platform and the GMP and regulatory track record behind it. Use the checklist below when you compare two or three vendors against the same written scope.

  • Therapeutic-area experience: ask for relevant programs in your specific area (allergen immunotherapy, food allergy, allergic rhinitis or asthma, prophylactic or therapeutic vaccine) and confirm the scientists and clinical staff who would run your study have done that exact work before.
  • Relevant models and assays: confirm the in vivo sensitization and challenge models you need, plus validated immunogenicity and serology assays (neutralizing antibody, serum bactericidal, specific IgE and IgG4, basophil activation, ELISpot, multiplex cytokine), with documented assay validation rather than research-grade methods alone.
  • Challenge-model and patient access: for allergy trials, check the vendor's access to an environmental exposure chamber or provocation suite, anaphylaxis-ready dosing facilities, and a sensitized patient population; for vaccines, check the ability to enroll large healthy, pediatric, or elderly cohorts on a seasonal or campaign timeline.
  • Regulatory track record: allergenic products and vaccines are biologics (CBER at the FDA, the EMA in Europe), so confirm direct experience with the pathway for your exact modality, an immunogenicity and potency strategy a regulator will accept, and a clean inspection history.
  • Data quality and safety discipline: look for clean, auditable data capture, strong pharmacovigilance and anaphylaxis reporting, DSMB experience, and cold-chain and sample-integrity controls for immunogenicity timepoints.
  • Capacity and timing: confirm current queue and realistic timelines against the season or campaign window your study depends on, since a great group booked past your pollen season is the wrong choice no matter how strong the science.
  • For CDMO work: match the platform exactly (allergen extract standardization, conjugate or subunit vaccine drug substance, adjuvant formulation, lyophilization, aseptic vaccine fill-finish), and confirm GMP status, scale, and stability and cold-chain capability.

Frequently asked questions

What is the difference between a CRO and a CDMO for an allergy or vaccine program?
A CRO runs the testing and the studies: assay development and immunogenicity work, in vivo sensitization and challenge models, and the GCP clinical trials including allergen challenge or vaccine immunogenicity cohorts. A CDMO makes the product: allergen extracts and standardized allergenic preparations, vaccine drug substance (conjugate, subunit, mRNA, or whole-cell), adjuvant formulation, lyophilization, and sterile fill-finish under GMP. Most programs in this indication need both. Through BioBridgeX you can source a CRO and a CDMO and contract them under one agreement rather than running two separate procurement and contracting tracks.
Which immunogenicity assays should a vendor be able to validate for a vaccine program?
It depends on the antigen, but the functional readouts matter more than raw binding titers. For most vaccines you will want neutralizing antibody assays and, for bacterial targets, serum bactericidal activity, alongside antigen-specific ELISA, ELISpot or fluorospot for cellular responses, and multiplex cytokine and flow cytometry panels for deeper immunophenotyping. The key question is whether the lab can validate those assays to support a regulatory filing, with documented accuracy, precision, and reference standards, not just run them as research methods. Settle the assay strategy and validation plan early, because a regulator will scrutinize how you measured the response, not only the number you report.
How do allergen challenge models like environmental exposure chambers work in a trial?
Challenge models give you a controlled, reproducible allergen exposure instead of waiting on natural pollen or unpredictable real-world contact. An environmental exposure chamber (EEC) delivers a fixed concentration of aeroallergen to seated subjects so symptom scores can be compared cleanly before and after treatment. Nasal and conjunctival provocation tests do the same at a single organ. For food allergy, the equivalent is double-blind placebo-controlled oral food challenge, which establishes a reaction threshold under medical supervision. All of these need a CRO with the right facility, an anaphylaxis-ready safety setup, and staff trained to run and score the challenge. They reduce the seasonality problem, though field trials tied to a real pollen season are still common and still time-boxed.
Why does timing matter so much for allergy and vaccine trials?
Both are calendar-driven in ways oncology trials are not. Aeroallergen field studies are tied to a pollen or mold season, so if you miss the enrollment and dosing window you wait roughly a year for the next one. Respiratory and seasonal vaccine work is similarly bound to circulating-disease seasons. That makes vendor capacity and lead time a first-order selection criterion: a strong CRO booked solid past your season is worse than a good one with an open slot now. Scope the trial against the specific window you are targeting and confirm the vendor can start, enroll, and dose inside it before you commit.
Can one vendor handle both the preclinical immunology and the clinical trial?
Some larger CROs offer both, and there is real value in continuity when the team that ran your immunogenicity models also carries the assays into the clinic. But the best preclinical immunology group and the best allergen-challenge or vaccine clinical-operations group are often different specialists, and forcing everything through one vendor can cost you on the half they are weaker at. A common and sound approach is to use a specialist for each stage. On BioBridgeX you can compare specialists side by side and still contract them under one agreement, so splitting the work across the right vendors does not multiply your contracting and invoicing overhead.
How does sourcing Allergy / Immunization vendors through BioBridgeX work, and what does it cost the buyer?
You describe the work (your program type, the assays or challenge models, the clinical or manufacturing scope) and you are matched with vetted CRO and CDMO vendors who do that specific work, with openly discoverable profiles rather than a sales demo before you can compare. You evaluate them on relevant experience and transparent quotes, then choose. The platform is free for buyers; vendors pay a flat 2% fee on a pay-when-paid basis, so quotes are not padded with buyer-side markups. When a program needs more than one vendor, which allergy and vaccine programs usually do, you contract once: one contract, one purchase order, and one invoice across every vendor, with BioBridgeX as the neutral vendor of record coordinating the relationship.

Source Allergy / Immunization work with one contract

Compare transparent quotes from qualified Allergy / Immunization CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes